Fundraising Fox
Vigil Neuroscience
acquired by SanofiCambridge, US · Founded 2020 · Delaware corporation · 6 known investors
Find your way into Vigil Neuroscience
Sign up to see every warm intro you have to Vigil Neuroscience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vigil Neuroscience team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Sanofi May 2025 · $470M ($8.00 per share cash, ~$470M equity value, plus CVR of $2.00/share (~$600M) tied to VG-3927 milestone) · source ↗
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
Founders & leadership
Board
Investors · 6
How we know: Atlas Venture's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Lightstone Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Pivotal Life Sciences's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Vida Ventures's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$215M disclosed across 3 rounds · 2020–2022
▶$75MraisedAug 2022 · 9 investors · PharmaceuticalsRule 506(b)
- Bruce BoothDirector
- Ivana Magovcevic-LiebischExecutive Officer, Director
- Christopher VerniExecutive Officer
- Mary ThistleDirector
- Stefan VitorovicDirector
- Evan ThackaberryExecutive Officer
- Cheryl BlanchardDirector
- Suzanne BruhnDirector
- Gerhard KoenigDirector
- Spyros PapapetropoulosExecutive Officer
- Jennifer ZiolkowskiExecutive Officer
- Shaan GandhiDirector
- Offering amount
- $75M
- Amount sold
- $75M
- Sales commissions
- $3.4M
- Placement agents
- Jefferies LLC
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$90MraisedAug 2021 · 19 investors · PharmaceuticalsRule 506(b)
- Stefan VitorovicDirector
- Shaan GandhiDirector
- Bruce BoothDirector
- Gerhard KoenigDirector
- Cheryl Blanchard, Ph. D.Director
- Jennifer ZiolkowskiExecutive Officer
- Clay ThorpDirector
- Ivana Magovcevic-LiebischExecutive Officer, Director
- Offering amount
- $90M
- Amount sold
- $90M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$50MraisedJun 2021 · 6 investors · BiotechnologyRule 506(b)
- Bruce BoothDirector
- Shaan GandhiDirector
- Gerhard KoenigDirector
- Ivana Magovcevic-LiebischExecutive Officer, Director
- Clay ThorpDirector
- Cheryl BlanchardDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Vigil Neuroscience do?
- An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
- Who are Vigil Neuroscience's investors?
- Vigil Neuroscience's investors include Atlas Venture, Lightstone Ventures, Pivotal Life Sciences, Vida Ventures, Hatteras Venture Partners, Longwood Fund.
- How much funding has Vigil Neuroscience raised?
- Vigil Neuroscience has disclosed $215M raised across 3 rounds.
- Who acquired Vigil Neuroscience?
- Vigil Neuroscience was acquired by Sanofi.
- Where is Vigil Neuroscience headquartered?
- Vigil Neuroscience is headquartered in Cambridge, US.